Tigecycline In-Vitro Surveillance Study In Taiwan

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

7902 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-08-31

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In-vitro surveillance study of tigecycline (Tygacil) in Taiwan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Local Susceptibility Patterns Associated With Tigecycline in Comparison to Other Antibiotics

NCT01311349

Infection

COMPLETED

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI

NCT00488761

Skin Diseases, Infectious

COMPLETED PHASE4

Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.

NCT00205816

Bacterial Infections

COMPLETED PHASE3

Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections

NCT00368537

Skin Diseases, Bacterial

COMPLETED PHASE4

Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment

NCT01072539

Complicated Skin and Skin Structure Infections Complicated Intra-abdominal Infections Community-Acquired Bacterial Pneumonia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Community Acquired Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

In-vitro testing

Intervention Type OTHER

This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

In-vitro testing

This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically relevant causative isolate (no duplicates) - The isolate must meet the laboratory criteria of "significant pathogen" and be considered the "probable causative agent" of a hospital or community acquired infection.
* Sources - All body sites are acceptable clinical sources for isolates to be included in this study (Intra-abdominal infection, tracheal secretion/bronchoalveolar lavage, blood culture, wound smear). However, no more than 10 % of all isolates can come from urine cultures.
* Within study group - Only isolates defined by the protocol are to be included.

Exclusion Criteria

* Limited isolates from sources - No more than 10 % of all isolates from this study will be derived from urine cultures.
* No banked or stored isolates.
* No duplicate isolates - Only one isolate per patient is permitted.
* Outside study group - Any isolate other than those defined by protocol.

Eligible Sex

ALL

Accepts Healthy Volunteers

No